Mumbai, Baltimore, June 05, 2019: Pharma major Lupin Limited (Lupin) announced the successful completion of the United States Food and Drug Administration (U.S. FDA) inspection at its Lupin Bioresearch Centre (LBC) without any observations. This is the fifth successive inspection without any 483 observations, indicating superior quality compliance maintained at this global bioresearch facility.
Lupin Bioresearch Centre (LBC) conducts the in-vivo and in-vitro bioequivalence studies for Lupin in Pune. This inspection also included review of studies done at the center’s new site at Lupin Research Park, Pune.
Commenting on the successful inspection, Mr. Nilesh Gupta, Managing Director, Lupin expressed satisfaction about the quality management system maintained in LBC and said “Such a high level of compliance reiterates Lupin’s commitment to high-quality standards across its world class research centres.”
Corporate Comm India(CCI Newswire)
Mumbai, June 21, 2024: According to India's Ministry of Health, brain stroke is the second…
The R&D Innovation Lab is dedicated to creating need-based solutions that go beyond existing options,…
By Dr Monil Parsana, Consultant Head and Neck Oncology Surgeon, HCG Hospital, Rajkot. The seemingly minor…
Non-Surgical, Painless and highly precise, single session with same day discharge Gold standard for brain…
By, Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital…
By Dr Chetan Jakaraddi, Consultant Trauma and Orthopedic Surgeon, MBBS, D’Ortho, MRCS (Edin), FRCS (UK)(T&O)…